Antibody Drug Conjugates have been designed as targeted therapy for cancer, and they are relatively new biological drugs. They combine the unique targeting abilities of monoclonal antibodies with the cytotoxic power of small molecule anticancer agents. The combination has been shown to reduce the toxic effects and enhance the therapeutic index of most ADCs. ADCs
read more..